The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Early outcome results of a phase I/II study for an IL-2/T-cell receptor fusion protein in combination with gemcitabine and cisplatin (GC) in patients with locally advanced or metastatic urothelial cancer.
Julio Hajdenberg
No relevant relationships to disclose
Danny Landau
No relevant relationships to disclose
Daniel A. Vaena
No relevant relationships to disclose
Mayer N. Fishman
No relevant relationships to disclose
Charles Joel Rosser
No relevant relationships to disclose
Mohammed M. Milhem
No relevant relationships to disclose
Jeffrey S. Weber
Consultant or Advisory Role - Altor BioScience
Virginia Rizzo
No relevant relationships to disclose
Pamela Zehr
No relevant relationships to disclose
Irene Williams-Elson
No relevant relationships to disclose
Peter Rhode
Employment or Leadership Position - Altor BioScience
Stock Ownership - Altor BioScience
Tessa Schutt
Employment or Leadership Position - Altor BioScience
Stock Ownership - Altor BioScience
Liza Hernandez
Employment or Leadership Position - Altor BioScience
Stock Ownership - Altor BioScience
Bee-Yau Huang
Employment or Leadership Position - Altor BioScience
Stock Ownership - Altor BioScience
Hing C. Wong
Employment or Leadership Position - Altor BioScience
Stock Ownership - Altor BioScience